

Concateno UK Limited

Annual Report and Financial Statements

Year Ended

31 December 2017

Company Number 02822149



Concateno UK Limited

Annual Report and financial statements for the year ended 31 December 2017

Contents

Page:

3	Report of the directors
5	Balance sheet
6	Notes to the financial statements

Directors

N Breare
P Beato

Registered Office

21 Blacklands Way
Abingdon
Oxfordshire
England
OX14 1DY

Company number

02822149

Concateno UK Limited

Report of the directors for the year ended 31 December 2017

The directors present their report together with the unaudited financial statements for the year ended 31 December 2017.

Results and dividends

The company did not trade in the financial year (2016: Non-trading) and therefore made neither a profit nor a loss (2016: £nil). A profit and loss account has therefore not been presented.

The directors do not recommend the payment of a dividend (2016: £nil).

Principal activities, trading review and future developments

The company is a wholly-owned subsidiary of Cozart Limited, which is 100% owned by Alere Toxicology Plc. With Cozart Limited shareholder approval, on 1 January 2012 the company hived-up its trade and assets to Alere Toxicology Plc. The transfer took place at net book value and the business is being continued by Alere Toxicology Plc. Since that date the company has not traded, but it has acted as agent for Alere Toxicology Plc.

Prior to the hive-up arrangement the principal activity of the company comprised the development, manufacture and sale of medical diagnostic tests and services, predominantly those used for the detection of drugs of abuse.

Principal risks and uncertainties

As the company no longer trades it is not subject to any significant risks.

Directors

The directors who held office during the year and up to the date of approval of these financial statements were as follows:

N Breare

B Yoor (Appointed 3 October 2017, Resigned 1 August 2018)

P Beato (Appointed 28 February 2018)

N James (Resigned 28 February 2018)

Statement of Directors' responsibilities

The directors are responsible for preparing the Report of the directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements;
- notify its shareholders in writing about the use of disclosure exemptions, if any, of FRS 102 used in the preparation of financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

Concateno UK Limited

Report of the directors (continued) for the year ended 31 December 2017

Statement of Directors' responsibilities (continued)

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Directors' indemnities

As permitted by the Articles of Association, the Directors have the benefit of an indemnity which is a qualifying third party indemnity provision as defined by Section 234 of the Companies Act 2006. The indemnity was in force throughout the last financial year and is currently in force.

Auditors

For the year ending 31 December 2017 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

On behalf of the Board



N Breare
Director

Date: 15/08/2018

Concateno UK Limited

Balance sheet at 31 December 2017

Company number 02822149	Note	2017 £000	2017 £000	2016 £000	2016 £000
Current assets					
Debtors	3	1,555		1,555	
		<u>1,555</u>		<u>1,555</u>	
Net assets			<u>1,555</u>		<u>1,555</u>
Capital and reserves					
Called up share capital	4	-		-	
Share premium	5	2,923		2,923	
Profit and loss account	5	(1,368)		(1,368)	
Total shareholders' funds	6	<u>1,555</u>		<u>1,555</u>	

The company has had no transactions in either the current or previous year and has made neither a profit or a loss (2016: £nil). A profit and loss account has therefore not been prepared.

For the year ending 31 December 2017 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

- the members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- the directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements were approved by the Board of Directors and authorised for issue on 15th August 2018.



N Breare
Director

The notes on pages 6 to 8 form part of these financial statements.

Concateno UK Limited

Notes to the financial statements for the year ended 31 December 2017

1 Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the year and to the preceding year.

a. Statement of compliance

The individual financial statements of Concateno UK Limited have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") and the Companies Act 2006.

b. General information and basis of accounting

Concateno UK Limited is a company incorporated in the United Kingdom under the Companies Act 2006. The nature of the Company's operations and its principal activities are set out in the Directors' report.

The financial statements have been prepared on a going concern basis under the historical cost convention and in accordance with Financial Reporting Standard 102 (FRS 102) issued by the Financial Reporting Council.

The company has adopted FRS102 in these financial statements. The directors have taken advantage of the transitional relief available to dormant companies by electing to retain the accounting policies for reported assets, liabilities and equity until there is any change to those balances or the company undertakes new transactions. As such, no adjustments have been made on transition to FRS 102.

The functional currency of Concateno UK Limited is considered to be pound sterling because that is the currency of the primary economic environment in which the Company operates.

Concateno UK Limited meets the definition of a qualifying entity under FRS 102. The company is a wholly owned subsidiary of the group headed by Abbott Laboratories, a company incorporated in the United States of America. The results of the company and its subsidiaries are included in the consolidated financial statements of Abbott Laboratories, which are publicly available and can be obtained from the address given in note 8. It has therefore taken advantage of certain disclosure exemptions available to it in respect of its financial statements. Exemptions have been taken in relation to the requirement to prepare a statement of cash flows. As a wholly owned subsidiary of a group whose financial statements are publicly available, the company is exempt by virtue of section 400 of the Companies Act 2006 from the requirement to prepare consolidated financial statements.

2 Directors

No directors were remunerated by the company during the year (2016: nil).

Payments to directors are made through the ultimate parent company, Abbott Laboratories or other group companies and it is not considered practicable to separately identify the remuneration paid to the directors for their services to this company.

There were no directors (2016: nil) in the company's defined contribution pension scheme during the year.

3 Debtors

	2017 £000	2016 £000
Amounts owed by parent and fellow subsidiary undertakings	1,555	1,555

All amounts shown under debtors fall due for payment within one year.

Concateno UK Limited

Notes to the financial statements (continued) for the year ended 31 December 2017

4 Called up share capital

	2017 Number	<i>Authorised</i> 2016 Number	2017 £	2016 £
"A" Ordinary shares of 0.001p each	11,483,538	11,483,538	115	115
"B" Ordinary shares of 0.001p each	2,161,278	2,161,278	21	21
"C" Ordinary shares of 0.001p each	4,167,289	4,167,289	42	42
	<u>17,812,105</u>	<u>17,812,105</u>	<u>178</u>	<u>178</u>
	2017 Number	<i>Allotted, called up and fully paid</i> 2016 Number	2017 £	2016 £
"A" Ordinary shares of 0.001p each	10,778,043	10,778,043	108	108
"B" Ordinary shares of 0.001p each	2,161,228	2,161,228	22	22
"C" Ordinary shares of 0.001p each	4,124,015	4,124,015	41	41
	<u>17,063,286</u>	<u>17,063,286</u>	<u>171</u>	<u>171</u>

The rights attaching to "A", "B", and "C" ordinary shares are the same except that "B" and "C" ordinary shares hold 51% of the votes on resolutions to:

- Declare a dividend of less than 25 per cent of profit before tax for the year;
- Change the memorandum and articles of association;
- Remove certain directors; and
- Issue share options.

5 Reserves

	Share premium account £'000	Profit and loss account £'000	Total £'000
At 1 January 2017	2,923	(1,368)	1,555
Result for the year	-	-	-
	<u>2,923</u>	<u>(1,368)</u>	<u>1,555</u>
At 31 December 2017			

Concateno UK Limited

Notes to the financial statements (continued) for the year ended 31 December 2017

6 Reconciliation of movement in shareholders' funds

	2017 £000	2016 £000
Result for the financial year	-	-
Increase in shareholders' funds	-	-
Opening shareholders' funds	1,555	1,555
Closing shareholders' funds	1,555	1,555

8. Related party transactions

The company has taken advantage of the exemption allowed by Financial Reporting Standard 8, "Related party disclosures", not to disclose any transactions with members of the group headed by Abbott Laboratories on the grounds of the voting rights are 100% controlled within that group and the company is included in consolidated financial statements.

9 Ultimate parent company

The company's ultimate parent company and controlling party is Abbott Laboratories, a company incorporated in the United States of America. The company's immediate parent company is Cozart Limited, a company incorporated in the United Kingdom.

The ultimate parent company is the only group to consolidate the financial statements of the company. Copies of the consolidated financial statements of Abbott Laboratories are available from Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois, USA.